In a benchmarking study that included such influential companies as
Abbott, Bayer, Roche, Merck, Pfizer, and Sanofi-Aventis, many key topics
were covered, including:
-- Bioequivalence Approach
-- Clinical Evaluation Approach
-- Lessons Learned
-- FTEs and Complexity
Among the key metrics gathered in this report are:
-- Past, Present and Future Number of FDC Drugs in Development
-- Additive vs. Synergistic Effects
-- Bioequivalence vs. Clinical Evaluation (Preferences and reasons why)
-- Starting Development Prior vs. Post Patent Expiration
-- Use of External Consultants
-- Bioequivalence - Timeframe from Conception to Final Formulation Launch
-- Clinical Evaluation - Timeframe from Conception to Final Formulation
Launch
-- Bioequivalence - Timeframe from Initiating Formulation Development to
Final Formulation Launch
-- Clinical Evaluation - Timeframe from Initiating Formulation Development
to Final Formulation Launch
-- Bioequivalence - Multiple Metrics
-- Clinical Evaluation - Multiple Metrics
-- Number of Drugs, FTEs and Timeframe to Reach First/Second Pilot PK
Study
-- Number of Drugs, FTEs and Timeframe to Reach Pivotal BE Study
-- Number of FTEs in Analytical Development
-- Timeframe from Initiating Development Work to CTM Manufacturing for
Class 1/2/4 drugs
For more information on this study or the Best Practice Database,
contact Robert Naylor at rnaylor@best-in-class.com or (919) 767-9244.
Interested parties may sign-up for a customized tour of the database via
the followi
'/>"/>
| SOURCE Best Practices, LLC Copyright©2008 PR Newswire. All rights reserved |